Furthermore, the combination of prexasertib with the PI3K/mTOR inhibitor samotolisib has shown synergistic or additive effects in most tumor models, effectively suppressing primary tumor growth in the MDA-MB-231 model and exhibiting preliminary clinical activity in heavily pretreated patients—indicating encouraging therapeutic potential (Hong et al., 2021). This evidence concerns the gene MTOR and neoplasm.